Validation of the human tissue factor/FVIIa complex as an antithrombotic target and the discovery of a synthetic...

Area of Science:

• Biochemistry
• Hematology
• Pharmacology

Background:

• The tissue factor (TF)/coagulation factor (F)VIIa complex is the primary initiator of the extrinsic coagulation pathway.
• Identifying effective antithrombotic targets is crucial for managing thrombotic disorders.

Purpose of the Study:

• To validate the TF/FVIIa complex as a therapeutic target for antithrombotic therapy.
• To discover and characterize novel inhibitors of TF/FVIIa-mediated coagulation.

Main Methods:

• Utilized a human thrombosis model with blood from FVII-deficient patients and healthy individuals under varying flow conditions.
• Employed an anti-TF monoclonal antibody, recombinant TF pathway inhibitor, and other agents for target validation.
• Structurally and biologically characterized the cyclic pentapeptide PN7051 and related peptides.

Main Results:

• PN7051 demonstrated dose-dependent inhibition of TF/FVIIa-induced coagulation and thrombus formation.
• Validation studies confirmed the TF/FVIIa complex as a viable antithrombotic target.
• PN7051 was found to disrupt interactions between the epidermal growth factor domain-2-like and catalytic domains of FVIIa.

Conclusions:

• The TF/FVIIa complex is a validated target for antithrombotic drug development.
• PN7051 is a promising peptide inhibitor with potential for further optimization.
• A peptidomimetics approach may enhance the antithrombotic efficacy of PN7051.